Matt O'Brien
Stock Analyst at Piper Sandler
(2.13)
# 2,842
Out of 5,182 analysts
204
Total ratings
40.48%
Success rate
-6.6%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADGM Adagio Medical Holdings | Initiates: Overweight | $3 | $1.48 | +102.70% | 1 | Apr 14, 2026 | |
| MDT Medtronic | Maintains: Neutral | $105 → $91 | $85.65 | +6.25% | 10 | Apr 1, 2026 | |
| MMED MiniMed Group | Initiates: Neutral | $16 | $14.02 | +14.12% | 1 | Mar 31, 2026 | |
| TELA TELA Bio | Maintains: Neutral | $1.25 → $1 | $0.73 | +36.46% | 8 | Mar 25, 2026 | |
| CNMD CONMED | Downgrades: Neutral | $55 → $39 | $37.91 | +2.88% | 15 | Mar 17, 2026 | |
| TNDM Tandem Diabetes Care | Upgrades: Overweight | $21 → $33 | $20.09 | +64.26% | 11 | Mar 17, 2026 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $50 → $28 | $24.52 | +14.19% | 6 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Overweight | $140 → $160 | $109.12 | +46.63% | 14 | Feb 25, 2026 | |
| GMED Globus Medical | Reiterates: Overweight | $90 → $115 | $92.76 | +23.98% | 13 | Jan 8, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Overweight | $27 → $30 | $20.41 | +46.99% | 2 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $14.12 | +27.48% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $75 | $61.23 | +22.49% | 13 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 → $25 | $10.82 | +131.05% | 4 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $26 → $32 | $12.18 | +162.73% | 2 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $155 → $82 | $88.37 | -7.21% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $16.53 | +33.09% | 3 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $10.68 | +68.54% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $7.36 | +63.04% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $121.62 | +35.67% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $3.83 | -8.62% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $130.22 | +7.51% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $201.47 | +53.87% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $331.47 | -0.44% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $28.88 | +73.13% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $24.62 | -35.01% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $63.42 | +81.33% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $4.99 | +140.48% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $338.38 | +24.12% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $13.68 | +82.75% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $0.68 | +338.85% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.94 | +14.21% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $94.78 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $4.47 | +235.57% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $69.38 | +56.75% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $18.14 | +341.01% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.18 | +187.08% | 1 | Jun 24, 2020 |
Adagio Medical Holdings
Apr 14, 2026
Initiates: Overweight
Price Target: $3
Current: $1.48
Upside: +102.70%
Medtronic
Apr 1, 2026
Maintains: Neutral
Price Target: $105 → $91
Current: $85.65
Upside: +6.25%
MiniMed Group
Mar 31, 2026
Initiates: Neutral
Price Target: $16
Current: $14.02
Upside: +14.12%
TELA Bio
Mar 25, 2026
Maintains: Neutral
Price Target: $1.25 → $1
Current: $0.73
Upside: +36.46%
CONMED
Mar 17, 2026
Downgrades: Neutral
Price Target: $55 → $39
Current: $37.91
Upside: +2.88%
Tandem Diabetes Care
Mar 17, 2026
Upgrades: Overweight
Price Target: $21 → $33
Current: $20.09
Upside: +64.26%
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Overweight
Price Target: $50 → $28
Current: $24.52
Upside: +14.19%
TransMedics Group
Feb 25, 2026
Maintains: Overweight
Price Target: $140 → $160
Current: $109.12
Upside: +46.63%
Globus Medical
Jan 8, 2026
Reiterates: Overweight
Price Target: $90 → $115
Current: $92.76
Upside: +23.98%
Kestra Medical Technologies
Dec 12, 2025
Maintains: Overweight
Price Target: $27 → $30
Current: $20.41
Upside: +46.99%
Nov 12, 2025
Reiterates: Overweight
Price Target: $18
Current: $14.12
Upside: +27.48%
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $61.23
Upside: +22.49%
Oct 31, 2025
Reiterates: Overweight
Price Target: $20 → $25
Current: $10.82
Upside: +131.05%
Oct 29, 2025
Reiterates: Overweight
Price Target: $26 → $32
Current: $12.18
Upside: +162.73%
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $88.37
Upside: -7.21%
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $16.53
Upside: +33.09%
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $10.68
Upside: +68.54%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $7.36
Upside: +63.04%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $121.62
Upside: +35.67%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $3.83
Upside: -8.62%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $130.22
Upside: +7.51%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $201.47
Upside: +53.87%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $331.47
Upside: -0.44%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $28.88
Upside: +73.13%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $24.62
Upside: -35.01%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $63.42
Upside: +81.33%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $4.99
Upside: +140.48%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $338.38
Upside: +24.12%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $13.68
Upside: +82.75%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $0.68
Upside: +338.85%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.94
Upside: +14.21%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $94.78
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $4.47
Upside: +235.57%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $69.38
Upside: +56.75%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $18.14
Upside: +341.01%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $4.18
Upside: +187.08%